Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $8
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $7 to $8.
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $7 to $8.